Dr Andrew Zhu joins Chemokine's clinical advisory board
This article was originally published in Scrip
Chemokine Therapeutics, a Canadian biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, has appointed Dr Andrew Zhuto its oncology clinical advisory board. Dr Zhu is an attending oncologist and the director of liver cancer research at Massachusetts General Hospital Cancer Center. He is also a staff physician at Dana-Farber Cancer Institute, and a member of Dana-Farber Harvard Cancer Center in Boston, Massachusetts.